In studies presented in this report, we found that Bim expression is not significantly induced in Her2+ breast cancer cells that are resistant to Lapatinib, either at baseline or acquired through continuous exposure to Lapatinib, and this lack of induction correlates with lack of apoptosis in response to Lapatinib treatment. Here, ERBB2 is linked to breast cancer.